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Abstract
Prior to the 21st century, genetic mechanisms that regulate sleep were largely unknown. In 1998, 
de Lecea et al. 1 and Sakurai et al. 2 reported the discovery of a gene they named hypocretin and 
orexin, respectively, which led to a revolution in our understanding of genetic and neuronal 
mechanisms that regulate sleep.
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Sleep is an essential behavioral state that is conserved throughout evolution. Prior to the 21st 
century, much of our understanding of sleep came from pharmacology and lesion studies in 
humans and other mammals. These relatively blunt tools were used to identify 
neurotransmitters, neuromodulators and brain regions that affect sleep, but allowed for only 
limited types of experiments, resulting in slow progress when it comes to dissecting the 
functional contributions of specific cell populations. The year 1998 marked the publication 
of two papers [1, 2] that would eventually transform our understanding of mechanisms that 
regulate sleep and wakefulness, even though neither paper mentions sleep.
One paper [1], from J. Gregor Sutcliffe’s lab at the Scripps Research Institute in La Jolla, 
California, was motivated by the notion that the hypothalamus is organized as a group of 
distinct nuclei that regulate a variety of homeostatic functions, including reproduction, 
feeding, circadian rhythms and sleep. It was hypothesized that specific genes are expressed 
in these nuclei and play key roles in their functions. Indeed, several such examples had 
already been identified. In the early to mid-1990s, to further test this hypothesis and identify 
additional genes that underlie the functions of specific hypothalamic nuclei, Kaare and 
Vigdis Gautvik (on sabbatical from the University of Oslo), together with Luis de Lecea and 
their colleagues in the Sutcliffe lab, undertook an mRNA subtraction screen to identify 
genes whose expression is enriched in the rodent hypothalamus compared to the 
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hippocampus and cerebellum [3]. They identified several such genes, one of which was 
particularly intriguing, as it was exclusively expressed in a relatively small number of 
neurons in the paraventricular hypothalamus, representing the type of specificity that they 
had hoped to find.
Based on this initial discovery, de Lecea, Tom Kilduff and their colleagues in the Sutcliffe 
lab isolated a full-length cDNA corresponding to this clone from rat and mouse [1]. This 
cDNA encoded for a predicted preproprotein (a proprotein precursor) containing two 
putative peptides that had high amino acid similarity with each other. As expected from the 
previous study [3], in situ hybridization and immunohistochemistry showed specific 
expression of the mRNA and protein in the dorsal lateral hypothalamus, with fibers 
projecting both within the posterior hypothalamus and also widely throughout the brain. The 
protein appeared to be present in synaptic vesicles, and one of the peptides could stimulate 
cultured hypothalamic neurons, consistent with the function of a peptide neurotransmitter. 
This novel gene was termed hypocretin due to its hypothalamic expression pattern and the 
similarity of the peptide sequences to members of the incretin family of hormones. While 
the hypocretin expression pattern was intriguing, its function was entirely unknown, and the 
authors could only speculate that it might act by binding to a G-protein coupled receptor 
(GPCR), as do other members of the incretin family of peptides.
The second 1998 paper [2], published one month later, identified the same gene using a 
completely different approach and for an entirely different reason. Genomic studies had 
identified many so-called “orphan” GPCRs whose ligands were unknown. Identifying the 
ligands and functions of these GPCRs was considered important, in part because GPCRs 
were, and still are, the largest class of protein that is targeted by drugs. Thus, identifying the 
ligands of orphan GPCRs could lead to new drug treatments for a variety of diseases. In 
order to identify endogenous ligands for orphan GPCRs, the Yanagisawa group first 
biochemically fractionated rat brain extracts using high-performance liquid chromatography. 
They then applied these extracts to over 50 cell lines that each expressed a different orphan 
GPCR, and assayed for GPCR activation. This heroic effort resulted in the identification of 2 
peptides, termed orexin-A and orexin-B (from the Greek word orexis for appetite), that 
activated cells expressing a specific GPCR, termed orexin receptor 1 (OX1R). Based on the 
peptide amino acid sequences, they isolated a cDNA that encodes for a preproprotein that 
contains both orexin-A and orexin-B. Unknown to them at the time, this was the same gene 
that the Sutcliffe group had discovered and named hypocretin. The Yanagisawa group next 
identified a GPCR similar to OX1R, which they termed OX2R, and showed that orexin-A 
and orexin-B can bind to both receptors. In agreement with the de Lecea et al. study, they 
found that orexin mRNA and protein were specifically expressed in the lateral and posterior 
hypothalamus, a brain region implicated by classical lesion studies in promoting feeding. 
Consistent with this observation, they found that central administration of orexin-A or 
orexin-B potently stimulated feeding, and that orexin expression was upregulated in 
response to fasting. Based on these results, the authors speculated that the orexin peptides 
may underlie the feeding-promoting role of the lateral and posterior hypothalamus.
The importance of these discoveries for sleep was revealed the following year, when the 
Yanagisawa lab reported that knocking out the hypocretin/orexin gene in mice results in a 
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behavioral phenotype similar to the human sleep disorder narcolepsy [4], and Emmanuel 
Mignot’s group showed that a heritable form of canine narcolepsy is due to a mutation in the 
OX2R gene, which his group named hypocretin receptor 2 [5]. These findings were soon 
shown to be relevant to human narcolepsy, with the discoveries that the hypocretin/orexin 
gene was mutated in a case of severe and early onset narcolepsy [6] and that narcoleptic 
individuals are deficient in hypocretin/orexin [6, 7].
Subsequent studies showed that signaling by the hypocretin/orexin neuropeptides, as well as 
the activity of hypocretin/orexin-expressing neurons, plays a key role in promoting and 
maintaining wakefulness in mammals [8, 9] and other vertebrates such as zebrafish [10]. As 
mentioned, one of the motivations for the de Lecea et al. and Sakurai et al. studies was to 
identify new drug targets. This goal was recently achieved, with the development and FDA 
approval of a drug that inhibits the hypocretin/orexin receptors and provides an effective 
treatment for insomnia [11]. Hypocretin/orexin receptor agonists have also recently been 
reported [12], which have the potential to be therapeutic for narcolepsy and other disorders 
associated with excessive sleep.
While I focused here on the impact of the discovery of hypocretin/orexin on the sleep field, 
it should be mentioned that the hypocretin/orexin system has also been shown to regulate 
other homeostatic processes, including: feeding, as alluded to by the Sakurai et al. 1998 
paper, and further explored in a vast body of follow up literature; energy homeostasis; 
reward-seeking; and more [13]. Back to the sleep field, the discoveries by de Lecea et al. and 
Sakurai et al. moved the field past anatomically defined brain regions and classical 
neurotransmitters into molecularly defined neuronal populations and the activity of specific 
genes within them. This shift, along with several technological advances, transformed the 
sleep field by enabling the interrogation of mechanisms that regulate sleep at the molecular 
and genetic levels. The discovery that a gene can profoundly affect sleep prompted the 
development of simpler invertebrate and vertebrate models to study sleep [14], including 
Drosophila melanogaster, Caenorhabditis elegans, and zebrafish, that allow for more 
sophisticated and powerful genetic approaches. These models have been used to perform 
large-scale screens for genes, neurons and drugs that affect sleep, which has led to the 
discovery of new mechanisms and revealed how some of these mechanisms interact. This 
approach recently came full circle with the publication by the Yanagisawa group of a heroic 
screen that identified novel sleep-regulating genes in mice [15]. The sleep field has recently 
undergone another revolution due to the use of cell-type-specific manipulation tools, such as 
optogenetics, to identify specific neuronal populations that promote sleep or wake states, and 
high-throughput sequencing methods to identify genes expressed in these neurons. These 
approaches, combined with new methods that enable large-scale recording of neuronal 
activity in the brain, have the potential to comprehensively identify the genetic and neuronal 
mechanisms that regulate sleep.
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